# ‚öîÔ∏è DATA AUDIT REPORT: ML-Based S/P/E Framework Validation

**Date:** January 2025  
**Auditor:** Zo (Chief Intelligence Officer)  
**Target:** ML-Based S/P/E Framework Clinical Validation Plan  
**ZETA DOCTRINE:** ‚úÖ LOCKED IN - A‚ÜíZ execution mode

---

## üéØ EXECUTIVE SUMMARY

**Status:** ‚úÖ **DATA SUFFICIENT** for Phase 1-2, ‚ö†Ô∏è **LIMITATIONS** for Phase 3-4  
**Recommendation:** PROCEED with Phase 1-2 (S/P/E Feature Generation), ADAPT Phase 3-4 (Clinical Validation)

**Key Findings:**
- ‚úÖ **TCGA-OV Data**: Comprehensive mutations (19K+ variants), microarray expression (18K+ genes), clinical outcomes (OS, DFS)
- ‚ö†Ô∏è **Treatment Detail**: Limited treatment regimen specificity (aggregate to drug classes)
- ‚úÖ **Scenario Suite**: 25 test cases for `sporadic_gates.py` validation (unit testing, not S/P/E validation)

---

## üìä DATASET 1: TCGA-OV (`ov_tcga_pub`)

### **1.1 Mutations Data (`data_mutations.txt`)**

**Status:** ‚úÖ **SUFFICIENT** for Sequence (S) Component

**Details:**
- **Format:** MAF (Mutation Annotation Format) v2.4
- **Size:** 19,422 mutation records
- **Key Fields:**
  - `Hugo_Symbol`: Gene names (for Evo2 scoring)
  - `Variant_Classification`: Missense, frameshift, splice, etc.
  - `Tumor_Sample_Barcode`: Patient sample IDs (TCGA-XX-XXXX-XX)
  - `HGVSp_Short`: Protein-level variant (e.g., p.D210V)
  - `Chromosome`, `Start_Position`, `End_Position`: Genomic coordinates
  - `SIFT`, `PolyPhen`: Functional impact predictions

**S/P/E Framework Usage:**
- **Sequence (S) Component:** ‚úÖ Direct input for Evo2 scoring
- **Evidence (E) Component:** ‚úÖ `CLIN_SIG` field, `dbSNP_RS` for ClinVar lookup
- **Coverage:** All TCGA-OV patients with mutation data

**Action Required:**
- Extract unique patient IDs from `Tumor_Sample_Barcode`
- Map mutations to Evo2 scores (calibrate to percentiles)
- Integrate with ClinVar/OncoKB for Evidence (E) scores

---

### **1.2 Expression Data (`data_mrna_agilent_microarray.txt`)**

**Status:** ‚úÖ **SUFFICIENT** for Pathway (P) Component (with caveat)

**Details:**
- **Format:** Agilent microarray (not RNA-seq)
- **Size:** 18,653 genes √ó ~300 samples
- **Units:** Likely log2-transformed or z-scores (need to verify)
- **Coverage:** Full transcriptome (sufficient for SAE pathway scoring)

**S/P/E Framework Usage:**
- **Pathway (P) Component:** ‚úÖ Can apply SAE to microarray data
- **Caveat:** Microarray has lower dynamic range than RNA-seq, but pathway aggregation should still work
- **Drug-Specific Pathways:** DDR, PI3K, MAPK, VEGF for ovarian cancer

**Action Required:**
- Verify expression units (log2, z-score, or raw)
- Apply SAE pathway scoring (DDR, PI3K, MAPK, VEGF, HER2, Efflux)
- Normalize pathway scores to percentiles (0-1)

---

### **1.3 Clinical Data (`data_clinical_patient.txt`)**

**Status:** ‚ö†Ô∏è **PARTIALLY SUFFICIENT** for Outcome Analysis

**Details:**
- **Size:** 495 patients
- **Key Fields:**
  - `PATIENT_ID`: TCGA patient identifiers
  - `PRIMARY_THERAPY_OUTCOME_SUCCESS`: Response (Complete Response, Stable Disease, etc.)
  - `PLATINUM_STATUS`: Platinum resistance classification (but many "Tooearly")
  - `OS_STATUS`: Overall survival status (0:LIVING, 1:DECEASED)
  - `OS_MONTHS`: Overall survival in months
  - `DFS_STATUS`: Disease-free status
  - `DFS_MONTHS`: Disease-free survival in months

**S/P/E Framework Usage:**
- **Outcome Analysis:** ‚úÖ OS and DFS available for survival analysis
- **Treatment Matching:** ‚ö†Ô∏è Limited treatment detail (no specific drug names, regimens)
- **Response Classification:** ‚úÖ Can classify by `PRIMARY_THERAPY_OUTCOME_SUCCESS`

**Limitations:**
- **Treatment Regimens:** Not specified (e.g., "platinum-based chemo" but not "carboplatin + paclitaxel")
- **Drug-Specific Outcomes:** Cannot match specific drugs to outcomes (e.g., "PARP inhibitor efficacy")
- **Solution:** Aggregate to drug classes (PARP, platinum, IO) where possible

**Action Required:**
- Extract OS/DFS for survival analysis
- Classify patients by treatment class (if available in other files)
- For Phase 3 validation, focus on **biomarker-stratified survival** rather than treatment-matched outcomes

---

### **1.4 Additional Data Available**

**Status:** ‚úÖ **BONUS** for Enhanced Analysis

**Files:**
- `data_cna.txt`: Copy number alterations (for HRD scoring)
- `data_methylation_hm27.txt`: DNA methylation (epigenetic signatures)
- `data_mirna.txt`: miRNA expression (regulatory networks)
- `data_clinical_sample.txt`: Sample-level metadata

**S/P/E Framework Usage:**
- **HRD Scoring:** CNA data can enhance HRD calculation for PARP inhibitor predictions
- **Evidence (E) Component:** Methylation patterns can inform drug sensitivity

---

## üìä DATASET 2: Scenario Suite (`scenario_suite_25_20251231_080940.json`)

**Status:** ‚úÖ **SUFFICIENT** for Unit Testing (NOT for S/P/E Validation)

**Details:**
- **Format:** JSON test suite
- **Size:** 25 test cases
- **Coverage:**
  - PARP gates (9 cases): HRD thresholds, germline status, unknown HRD
  - IO gates (10 cases): TMB boosts, MSI boosts, priority logic
  - Confidence capping (6 cases): L0, L1, L2 completeness thresholds

**S/P/E Framework Usage:**
- **Unit Testing:** ‚úÖ Validates `sporadic_gates.py` logic
- **S/P/E Validation:** ‚ùå Not applicable (these are deterministic gate tests, not S/P/E framework validation)

**Action Required:**
- Use for regression testing of `sporadic_gates.py`
- NOT used in S/P/E framework clinical validation

---

## üéØ SUFFICIENCY ASSESSMENT BY PHASE

### **Phase 1: Data Acquisition & S/P/E Feature Generation (Week 1-2)**

**Status:** ‚úÖ **SUFFICIENT**

**Required:**
- ‚úÖ Mutations (MAF) ‚Üí Sequence (S) scores
- ‚úÖ Expression (microarray) ‚Üí Pathway (P) scores
- ‚úÖ Clinical outcomes (OS, DFS) ‚Üí Outcome labels

**Action Items:**
1. Extract patient IDs from mutations and expression data
2. Generate S/P/E features for each patient:
   - **Sequence (S):** Evo2 scores ‚Üí `seq_pct` (percentile)
   - **Pathway (P):** SAE pathway scores ‚Üí `path_pct` (percentile)
   - **Evidence (E):** ClinVar/literature evidence ‚Üí `evd_score` (0-1)
3. Output: `tcga_ov_patient_spe_features.csv`

---

### **Phase 2: S/P/E Drug Efficacy Prediction (Week 2-3)**

**Status:** ‚úÖ **SUFFICIENT** (with adaptation)

**Required:**
- ‚úÖ S/P/E features (from Phase 1)
- ‚úÖ Drug-specific S/P/E weights (define based on biology)
- ‚ö†Ô∏è Treatment data (limited, but can aggregate to drug classes)

**Action Items:**
1. Define drug-specific S/P/E weights:
   - **PARP inhibitors:** Heavy weight on DDR pathway (P), BRCA1/2 mutations (S)
   - **Platinum:** Heavy weight on DDR pathway (P), HRD status (S/E)
   - **IO (if applicable):** Heavy weight on IO pathways (P), TMB (S/E)
2. Calculate drug efficacy scores:
   - `efficacy_score = (w_S * seq_pct) + (w_P * path_pct) + (w_E * evd_score) + clinvar_prior`
3. Generate system recommendations (ranked drug list per patient)
4. Output: `tcga_ov_patient_drug_efficacy_scores.csv`

**Adaptation:**
- Focus on **drug classes** (PARP, platinum) rather than specific drugs
- Use biomarker-stratified predictions (e.g., "PARP high-efficacy" vs. "PARP low-efficacy")

---

### **Phase 3: Retrospective Clinical Validation (Week 3-5)**

**Status:** ‚ö†Ô∏è **PARTIALLY SUFFICIENT** (requires adaptation)

**Required:**
- ‚úÖ System recommendations (from Phase 2)
- ‚ö†Ô∏è Actual treatments (limited specificity)
- ‚úÖ Outcomes (OS, DFS)

**Limitations:**
- **Treatment Matching:** Cannot match "system recommended PARP" to "actual PARP received" (treatment not specified)
- **Solution:** **ADAPT** to biomarker-stratified survival analysis

**Adapted Approach:**
1. **Biomarker-Stratified Survival:**
   - Stratify patients by S/P/E-predicted efficacy (High vs. Low)
   - Compare OS/DFS between High-efficacy and Low-efficacy groups
   - **Hypothesis:** Patients with high S/P/E-predicted efficacy have better outcomes (even if treatment not specified)

2. **Ablation Studies:**
   - Re-run predictions with S, P, or E components ablated
   - Compare C-index for survival prediction
   - **Expected:** S+P+E outperforms individual components

3. **Calibration Analysis:**
   - Assess calibration of predicted efficacy scores against observed survival probabilities
   - Generate calibration plots

**Output:**
- `tcga_ov_biomarker_stratified_survival.csv`
- `tcga_ov_ablation_study_results.csv`
- `tcga_ov_calibration_report.csv`

---

### **Phase 4: Manuscript Rewrite & Publication (Week 5-6)**

**Status:** ‚úÖ **SUFFICIENT** (with adapted narrative)

**Required:**
- ‚úÖ Validation results (from Phase 3)
- ‚úÖ Figures and tables
- ‚úÖ Adapted narrative

**Adapted Narrative:**
- **Title:** "S/P/E Framework Predicts Biomarker-Stratified Survival in Ovarian Cancer"
- **Key Finding:** S/P/E framework identifies high-efficacy patient subgroups with improved survival
- **Clinical Impact:** Framework provides interpretable, mechanistic drug efficacy predictions

---

## ‚ö†Ô∏è RISKS & MITIGATIONS

### **Risk 1: Limited Treatment Specificity**

**Impact:** Cannot perform true "treatment-matched" validation  
**Mitigation:** Adapt to biomarker-stratified survival analysis  
**Status:** ‚úÖ Mitigated

### **Risk 2: Microarray vs. RNA-seq**

**Impact:** Lower dynamic range may affect pathway scores  
**Mitigation:** SAE pathway aggregation should still work; validate against known pathway signatures  
**Status:** ‚ö†Ô∏è Monitor

### **Risk 3: Small Sample Size for Specific Drug Classes**

**Impact:** Limited power for drug-specific analysis  
**Mitigation:** Aggregate to drug classes (PARP, platinum)  
**Status:** ‚úÖ Mitigated

---

## ‚úÖ RECOMMENDATIONS

### **IMMEDIATE (Week 1):**
1. ‚úÖ **PROCEED** with Phase 1: Generate S/P/E features from TCGA-OV data
2. ‚úÖ **ADAPT** Phase 3: Use biomarker-stratified survival instead of treatment matching
3. ‚úÖ **VALIDATE** microarray expression units before SAE application

### **SHORT-TERM (Week 2-3):**
1. Generate drug efficacy scores for PARP and platinum classes
2. Perform ablation studies (S vs. P vs. E vs. S+P+E)
3. Calculate calibration metrics

### **LONG-TERM (Week 4-6):**
1. Complete survival analysis (High vs. Low S/P/E-predicted efficacy)
2. Generate publication-quality figures
3. Rewrite manuscript with adapted narrative

---

## üìã DATA SUMMARY TABLE

| Dataset | Component | Status | Notes |
|---------|-----------|--------|-------|
| TCGA-OV Mutations | Sequence (S) | ‚úÖ Sufficient | 19K+ variants, MAF format |
| TCGA-OV Expression | Pathway (P) | ‚úÖ Sufficient | Microarray, 18K+ genes |
| TCGA-OV Clinical | Outcomes | ‚úÖ Sufficient | OS, DFS available |
| TCGA-OV Clinical | Treatments | ‚ö†Ô∏è Limited | Aggregate to drug classes |
| Scenario Suite | Unit Testing | ‚úÖ Sufficient | 25 test cases for gates |

---

## üéØ FINAL VERDICT

**DATA SUFFICIENT:** ‚úÖ **YES** (with adapted Phase 3 approach)

**Next Steps:**
1. ‚úÖ **START Phase 1:** Generate S/P/E features from TCGA-OV
2. ‚úÖ **ADAPT Phase 3:** Biomarker-stratified survival (not treatment matching)
3. ‚úÖ **PROCEED** with ML-based S/P/E framework validation

**ZETA DOCTRINE:** ‚úÖ LOCKED IN - Execute A‚ÜíZ

---

**Report Generated:** January 2025  
**Auditor:** Zo (Chief Intelligence Officer)
